Has Yevgeniy Shildkrot, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,405 in general payments to Yevgeniy Shildkrot, MD across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yevgeniy Shildkrot, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yevgeniy Shildkrot, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yevgeniy Shildkrot, MD

Ophthalmology · Fishersville, VANPI 1427241108

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,905 of the $4,405 with a category attached, or 88.6%. It is spread thinly across 18 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.

$4,405in general payments, 2019–2025

Across 92 payments — averaging $47.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astellas Pharma US Inc$865
Immunocore Limited$785
Regeneron Healthcare Solutions, Inc.$657
AbbVie$357
Apellis Pharmaceuticals, Inc.$292
Topcon Healthcare, Inc.$252
plus $1K from 12 others

$8,338in research payments, 2019–2025

Across 1 payment — averaging $8338.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$8K

What the payments were for

Speaking & faculty fees$50011%
Food & beverage$3,90589%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astellas Pharma US Inc	14	$865
Immunocore Limited	5	$785
Regeneron Healthcare Solutions, Inc.	15	$657
AbbVie(2 entities)	17	$357
Apellis Pharmaceuticals, Inc.	10	$292
Topcon Healthcare, Inc.	1	$252
Amgen(2 entities)	4	$215
Regeneron	2	$165
Genentech USA, Inc.	7	$160
Genentech, Inc.	1	$124
Bausch & Lomb Americas Inc.	6	$117
Sun Pharmaceutical Industries Inc.	1	$116
Alimera Sciences, Inc.	1	$106
Mallinckrodt Hospital Products Inc.	3	$77
Eyepoint US, Inc.	1	$45
ANI Pharmaceuticals, Inc.	2	$31
Coherus Oncology, Inc.	1	$26
Alcon	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,405 in reported general payments places this provider in the 85th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia →

Medicare billing

Part B allowed, 2024

$3,990,080

Medicare patients

952

Services billed

70,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	292	$10,075
Ketorolac Tromethamine	149	$2,764
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	117	$1,549
Brimonidine Tartrate	85	$1,188
Difluprednate	20	$969
Ciprofloxacin Hcl	70	$895
ErythromycinErythromycin Base	63	$801
Latanoprost	93	$727
Dorzolamide Hcl	33	$641
MoxifloxacinMoxifloxacin Hcl	18	$447
Timolol Maleate	26	$310
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	17	$207
Prednisone	13	$43

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Fishersville

Ethnie JonesRichmond$2M
Elizabeth Yeu-LinNorfolk$1.7M
John SheppardNorfolk$1.1M
Constance OkekeNorfolk$800K
Marc OdrichCharlottesville$497K
Jayakrishna AmbatiCharlottesville$116K
Thomas JolyNorfolk$95K
Stephen ScoperNorfolk$88K
Leonard RappaportPortsmouth$85K
Soheila RostamiReston$73K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →